BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.44
-0.02 (-0.20%)
Nov 17, 2026, 10:20 AM EST - Market open
BioCryst Pharmaceuticals Market Cap
BioCryst Pharmaceuticals has a market cap or net worth of $1.91 billion as of November 17, 2026. It is the 6,618th most valuable company in the world and the 1,765th biggest in the United States. Its market cap has increased by 28.34% in one year.
Market Cap
1.91B
Enterprise Value
2.37B
1-Year Change
28.34%
Global Rank
Country Rank
#1,765 United States
Category
ChartMarket Cap Chart
Since December 1, 1998, BioCryst Pharmaceuticals's market cap has increased from $100.40M to $1.91B, an increase of 1,805.40%. That is a compound annual growth rate of 11.11%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 17, 2026 | 1.91B | 16.49% |
| Dec 31, 2025 | 1.64B | 5.43% |
| Dec 31, 2024 | 1.56B | 26.96% |
| Dec 29, 2023 | 1.23B | -42.68% |
| Dec 30, 2022 | 2.14B | -14.12% |
| Dec 31, 2021 | 2.49B | 89.46% |
| Dec 31, 2020 | 1.32B | 245.25% |
| Dec 31, 2019 | 381.00M | -56.94% |
| Dec 31, 2018 | 884.80M | 83.11% |
| Dec 29, 2017 | 483.20M | 3.49% |
| Dec 30, 2016 | 466.90M | -38.31% |
| Dec 31, 2015 | 756.80M | -13.40% |
| Dec 31, 2014 | 873.90M | 94.59% |
| Dec 31, 2013 | 449.10M | 522.02% |
| Dec 31, 2012 | 72.20M | -35.36% |
| Dec 30, 2011 | 111.70M | -51.92% |
| Dec 31, 2010 | 232.30M | -7.38% |
| Dec 31, 2009 | 250.80M | 378.63% |
| Dec 31, 2008 | 52.40M | -77.65% |
| Dec 31, 2007 | 234.50M | -30.60% |
| Dec 29, 2006 | 337.90M | -23.72% |
| Dec 30, 2005 | 443.00M | 252.71% |
| Dec 31, 2004 | 125.60M | 3.37% |
| Dec 31, 2003 | 121.50M | 614.71% |
| Dec 31, 2002 | 17.00M | -75.61% |
View and export this data all the way back to 1998. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Xeris Biopharma Holdings | 3.04B |
| HUTCHMED (China) | 2.55B |
| Regencell Bioscience Holdings | 2.45B |
| Perrigo Company | 2.25B |
| Prestige Consumer Healthcare | 2.19B |
| Trulieve Cannabis | 2.10B |
| Eton Pharmaceuticals | 1.84B |
| ANI Pharmaceuticals | 1.51B |